Skip to main content

Advertisement

SpringerLink
Log in

Amyloid-Beta Associated with Chitosan Nano-Carrier has Favorable Immunogenicity and Permeates the BBB

  • Brief/Technical Note
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Subfragments of amyloid-beta (Aβ) appear to protect neurons from Alzheimer’s disease (AD). The permeability of the blood–brain barrier (BBB) has limited in vivo research. The aim of this study is to explore permeation of the BBB by chitosan nanoparticles loaded with Aβ and to evaluate immunogenicity of these particles. Chitosan microspheres were prepared by mechanical stirring emulsification methods combined with chemical crosslinking. Morphological characteristics of the nanoparticles were examined using high-resolution transmission electron microscopy. The peptide association efficiency was determined by high-performance liquid chromatography. Fluorescently labeled chitosan nanoparticle-intramembranous fragments of Aβ (NP-IF-A) were administered systemically to mice in order to evaluate brain translocation by fluorescence microscopy. The immunogenicity of the nano-vaccine was determined by enzyme-linked immunosorbent assay (ELISA). All nanoparticles analyzed were well-separated, roughly spherical structures with uniform particle size distribution in the range of 15.23 ± 10.97 nm. The peptide association efficiency was 78.4%. The brain uptake efficiency of nano-antigen was 80.6%; uptake efficiency of antigen alone was only 20.6%. ELISA showed that the nano-vaccine had favorable immunogenicity. A chitosan nano-carrier for Aβ allowed permeation of the BBB and was non-immunogenic. These findings indicate that this novel targeted nano-vaccine delivery system can be used as a carrier for Aβ. This system will further research of peptide vaccines for AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer’s disease. Trends Neurosci. 1993;16:403–9. doi:10.1016/0166-2236(93)90008-A.

    Article  PubMed  CAS  Google Scholar 

  2. Lopez OL, Rabin BS, Huff FJ, Rezek D, Reinmuth OM. Serum autoantibodies in patients with Alzheimer’s disease and vascular dementia and in nondemented control subjects. Stroke. 1992;23:1078–83.

    PubMed  CAS  Google Scholar 

  3. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408:982–5. doi:10.1038/35050116.

    Article  PubMed  CAS  Google Scholar 

  4. Soto C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer’s disease. Mol Med Today. 1999;5:343–50.

    Article  PubMed  CAS  Google Scholar 

  5. Fradinger EA, Monien BH, Urbanc B, Lomakin A, Tan M, Li H, et al. C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity. Proc Natl Acad Sci U S A. 2008;105:14175–80. doi:10.1073/pnas.0807163105.

    Article  PubMed  CAS  Google Scholar 

  6. Bernkop-Schnurch A, Krajicek ME. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan–EDTA conjugates. J. Control. Release. 1998;50:215–23. doi:10.1016/S0168-3659(97)00136-3.

    Article  PubMed  CAS  Google Scholar 

  7. Borges O, Borchard G, de Sousa A, Junginger HE, Cordeiro-da-Silva A. Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers. Int. J. Pharm. 2007;337:254–64. doi:10.1016/j.ijpharm.2007.01.021.

    Article  PubMed  CAS  Google Scholar 

  8. Jameela SR, Kumary TV, Lal AV, Jayakrishnan A. Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system. J Control Release. 1998;52:17–24. doi:10.1016/S0168-3659(97)00187-9.

    Article  PubMed  CAS  Google Scholar 

  9. Aktaş Y, Yemisci M, Andrieux K, Gürsoy RN, Alonso MJ, Fernandez-Megia E, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem. 2005;16:1503–11.

    Article  PubMed  Google Scholar 

  10. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev. Ind. Phar. 1998;24:979–93.

    Article  CAS  Google Scholar 

  11. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 1998;15:1326–31.

    Article  PubMed  CAS  Google Scholar 

  12. Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects—an update. J. Pharm. Pharmacol. 2001;53:1047–67.

    Article  PubMed  CAS  Google Scholar 

  13. Kumbar SG, Kulkarni AR, Minabhavi MA. Crosslinked chitosan microspheres for encapsulation of diclofenac sodium: effect of crosslinking agent. J. Microencapsul. 2002;19:173–80.

    Article  PubMed  CAS  Google Scholar 

  14. Jameela SR, Kumary TV, Lal AV, Jayakrishnan A. Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system. J. Control Rel. 1998;52:17–24. doi:10.1016/S0168-3659(97)00187-9.

    Article  CAS  Google Scholar 

  15. Huang RG, Schwartz JB, Ofner CM III. Microencapsulation of chlorpheniramine maleate-resin particles with crosslinked chitosan for sustained release. Pharm. Dev. Technol. 1999;4:107–15.

    PubMed  CAS  Google Scholar 

  16. Pavanetto F, Perugini P, Conti B, Modena T, Genta I. Evaluation of process parameters involved in chitosan microspheres preparation by the o/w/o multiple emulsion method. J. Microencaps. 1996;13:679–88.

    Article  CAS  Google Scholar 

  17. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm. 2002;244:105–15. doi:10.1016/S0378-5173(02)00315-0.

    Article  PubMed  CAS  Google Scholar 

  18. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–77. doi:10.1038/22124.

    Article  PubMed  CAS  Google Scholar 

  19. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature. 2000;408:979–82. doi:10.1038/35050110.

    Article  PubMed  CAS  Google Scholar 

  20. Kim MS, Sung MJ, Seo SB, Yoo SJ, Lim WK, Kim HM. Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta. Neuroscience Letters. 2002;321:105–9. doi:10.1016/S0304-3940(02)00066-6.

    Article  PubMed  CAS  Google Scholar 

  21. Mori T, Okumura M, Matsuura M, Ueno K, Tokura S, Okamoto Y, et al. Effects of chitin and its derivatives on the proliferation and cytokine production of fibroblasts in vitro. Biomaterials. 1997;18:947–51. doi:10.1016/S0142-9612(97)00017-3.

    Article  PubMed  CAS  Google Scholar 

  22. Pae HO, Seo WG, Kim NY, Oh GS, Kim GE, Kim YH, et al. Induction of granulocytic differentiation in acute promyelocytic leukemia cells (HL-60) by water-soluble chitosan oligomer. Leuk. Res. 2001;25:339–46. doi:10.1016/S0145-2126(00)00138-7.

    Article  PubMed  CAS  Google Scholar 

  23. Nishimura K, Nishimura S, Seo H, Nishi N, Tokura S, Azuma I. Effect of multiporous microspheres derived from chitin and partially deacetylated chitin on the activation of mouse peritoneal macrophages. Vaccine. 1987;5:136–40.

    Article  PubMed  CAS  Google Scholar 

  24. Shibata Y, Foster LA, Metzger WJ, Myrvik QN. Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-d-glucosamine, in mice. Infect. Immunol. 1997;65:1734–41.

    CAS  Google Scholar 

  25. Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: An overview, structure, regulation and clinical implications. Neurobiol. Dis. 2004;16:1–13. doi:10.1016/j.nbd.2003.12.016.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Construct Program of the Key Discipline in Hunan Province, Natural Science Foundation of Hunan Province, China (No.08JJ307), and National High Tech 863 Grant (Project No. 2007AA021901).

Author information

Authors and Affiliations

  1. Department of Physiology, Xiangya Medical College, Central South University, Changsha, 410078, China

    Zhang Songjiang & Wu Lixiang

  2. Department of Physiology, Henan College of Traditional Chinese Medicine, Zhengzhou, 450000, China

    Zhang Songjiang

Authors
  1. Zhang Songjiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wu Lixiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wu Lixiang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Songjiang, Z., Lixiang, W. Amyloid-Beta Associated with Chitosan Nano-Carrier has Favorable Immunogenicity and Permeates the BBB. AAPS PharmSciTech 10, 900–905 (2009). https://doi.org/10.1208/s12249-009-9279-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-009-9279-1

Key words

Search

Navigation